Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGC001 Injection in Chinese Patients With Acute Anterior STEMI Undergoing Primary PCI (Phase II)
CTR20255162Phase 2Active
- Sponsor
- Sungen Biomedical
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SGC001 in myocardial infarction (MI), sponsored by Sungen Biomedical. Started Mar 2026; status: active.
02
Drugs
SGC001
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on CTR20255162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255162.